Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial - Javle, Milind; Borbath, I.; Clarke, S.; Hitre, E.; Louvet, C.; Macarulla, T.; Oh, D.; Spratlin, J.; Valle, J.; Weiss, Karl Heinz; Berman, C.; Howland, M.; et al. (Annals of oncology, 2019)
Poster
Conference abstract P-225
Gesehen am 03.07.2020